• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 16, 2021 at 11:32: AM
via Merck presented new data from the Phase III CLEAR trial (KEYNOTE-581/Study 307) at the virtual 2021 Genitourinary Cancers Symposium (ASCO GU) of its checkpoint inhibitor Keytruda (pembrolizumab) and Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) in renal cell carcinoma. The data was also published in the New England Journal of Medicine.

article source
 

<



Similar threads

cafead
ESMO: Despite checkered past, Merck&#039;s Keytruda-Lenvima pairing looks to change practice in liver cancer subtype
Replies
0
Views
30
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Merck&#039;s Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval
Replies
0
Views
23
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
&#039;We&#039;re going to miss the next Keytruda&#039;: Lilly, Merck, Gilead and PhRMA CEOs talk IRA consequences
Replies
0
Views
28
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Samsung joins biosimilar race for Merck &amp; Co.&#039;s Keytruda blockbuster
Replies
0
Views
93
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Merck seeks more deals to prepare for Keytruda&#039;s revenue decline
Replies
0
Views
62
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote